
|Articles|January 27, 2021
Supplements and Featured Publications
- The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
The Role of Lipoprotein(a) As a Biomarker to Assess Cardiovascular Risk
Advertisement
This publication is sponsored by Novartis AG.
This Clinical Practice Brief provides an overview of the genetic cardiovascular risk biomarker lipoprotein a (Lp[a]), as well as its importance as an independent risk factor for cardiovascular disease, the prevalence of elevated Lp(a) levels among the global population, and recommendations for lipid management.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
2
Patients Face New Care Complexities as DTC Options Expand
3
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
4
Louisiana Delivers Innovative Cancer Treatments, but Ensuring Access Is a Work in Progress
5














































